Cosmetic ingredients maker United-Guardian's Q1 revenue and profit rise

United-Guardian, Inc.

0.00

Overview

U.S. specialty ingredients maker's Q1 revenue and net income rose yr/yr
Growth driven by higher pharmaceutical and cosmetic ingredient sales
Q1 income supplemented by settlement income from contract manufacturer shutdown in late 2023

Outlook

Company expects sales to continue increasing in 2026

Result Drivers

PHARMACEUTICAL SALES - Q1 pharmaceutical sales rose 24%, driven by increased demand for Renacidin
COSMETIC INGREDIENTS - Sales of cosmetic ingredients increased 21%, mainly due to a 45% rise in purchases by distributor ASI as it resumed regular buying after working off excess inventory
SETTLEMENT INCOME - Q1 net income was supplemented by settlement income related to a contract manufacturer shutdown in late 2023, which resulted in lost Renacidin sales

Company press release: ID:nGNX8k5TrH

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue		$2.87 mln
Q1 EPS		$0.18

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.